ethnopharmacolog
relev
pelargonium
sidoid
dc
geraniacea
popular
medicin
plant
use
tradit
medicin
treatment
gastrointestin
ailment
transform
phytopharmaceut
ep
treat
respiratori
tract
infect
increas
intern
demand
pelargonium
sidoid
led
localis
overexploit
wild
popul
southern
africa
aim
review
provid
synthesi
current
state
scientif
knowledg
phytochem
pharmacolog
toxicolog
properti
pelargonium
sidoid
well
potenti
role
plant
biotechnolog
conserv
review
highlight
knowledg
gap
research
area
materi
method
comprehens
literatur
search
involv
mainli
electron
librari
sourc
inform
use
collat
synthesis
publish
data
result
experiment
result
vitro
studi
indic
bioactiv
phytochem
constitu
pelargonium
sidoid
may
possess
direct
antimicrobi
effect
instead
act
interf
microbi
bind
host
cell
receptor
inhibit
key
enzym
product
antimicrobi
effector
molecul
nitric
oxid
interferon
ifn
host
cell
furthermor
clinic
evalu
randomis
doubleblind
placebocontrol
trial
demonstr
benefici
effect
pelargonium
sidoid
treatment
respiratori
tract
infect
side
effect
howev
lack
adequ
inform
safeti
evalu
plant
hand
increas
demand
pelargonium
sidoid
led
localis
illeg
harvest
wild
plant
conclus
pharmacolog
data
report
literatur
suggest
pelargonium
sidoid
show
benefici
effect
treatment
respiratori
tract
infect
howev
studi
requir
elucid
mode
action
activ
constitu
exhibit
treatment
respiratori
tract
infect
health
condit
caus
microbi
attack
furthermor
pharmacolog
use
pelargonium
sidoid
must
take
cognis
broader
context
involv
need
conservationfriendli
approach
utilis
regard
plant
biotechnolog
applic
play
meaning
role
holist
conserv
strategi
pelargonium
sidoid
dc
synonym
pelargonium
sidaefolium
thunb
r
knuth
common
name
umckaloabo
uvendl
kalwerbossi
khoaara
e
nyenyan
famili
geraniacea
perenni
geophyt
predominantli
found
eastern
cape
provinc
south
africa
lesotho
highland
plant
adapt
wide
altitudin
rang
span
near
sea
level
eastern
cape
lesotho
highland
newton
et
al
plant
wide
use
local
commun
tradit
medicin
cure
variou
ailment
includ
diarrhoea
colic
gastriti
tuberculosi
cough
hepat
disord
menstrual
complaint
gonorrhoea
brendler
van
wyk
coll
et
al
root
also
main
ingredi
remedi
use
treat
stomach
ailment
known
instila
infant
hutch
et
al
powder
plant
materi
soak
water
use
facial
cream
treatment
skin
pimpl
lewu
et
al
indic
pelargonium
sidoid
may
exhibit
antibacteri
properti
probabl
compel
ethnobotan
use
pelargonium
sidoid
treatment
tuberculosi
subsequ
led
introduct
europ
late
bladt
wagner
brendler
van
wyk
tradit
ethnoveterinari
applic
pelargonium
sidoid
includ
use
root
decoct
anthelmint
remedi
calv
hutch
et
al
boil
leav
protect
wound
maggot
prevent
purg
hors
brendler
van
wyk
extract
obtain
soak
root
water
administ
oral
treatment
dysenteri
cattl
lewu
et
al
base
medicin
properti
treatment
respiratoryrel
ailment
pelargonium
sidoid
formul
phytopharmaceut
name
ep
umckaloabo
dr
willmar
schwabe
gmbh
co
kg
pharmaceut
germani
linctagon
nativa
south
africa
commerci
success
umckaloabo
attribut
numer
factor
includ
year
extens
scientif
clinic
research
gerick
hand
neglig
research
bourdett
motsamai
done
evalu
efficaci
safeti
linctagon
mainli
contain
mg
pelargonium
sidoid
mg
vitamin
c
mg
bromelain
mg
quercetin
mg
zinc
review
provid
synthesi
state
scientif
knowledg
pharmacolog
safeti
evalu
pelargonium
sidoid
well
explor
potenti
plant
biotechnolog
applic
conserv
extens
use
pelargonium
sidoid
tradit
medicin
coupl
popularis
modern
medic
system
europ
led
upsurg
scientif
explor
chemic
composit
effort
identifi
activ
principl
result
consider
bodi
literatur
explor
phytochem
properti
pelargonium
sidoid
et
al
et
al
hauer
et
al
kayser
kolodziej
et
al
schoetz
et
al
detail
phytochemistri
plant
comprehens
summaris
excel
review
kolodziej
howev
identif
individu
chemic
constitu
respons
specif
pharmacolog
activ
remain
larg
elus
chemic
constitu
root
ethanol
extract
plant
consist
larg
oligoand
polymer
proanthocyanidin
base
gallocatechin
epigallocatechin
moieti
theisen
muller
pharmacolog
efficaci
pelargonium
sidoid
partli
attribut
biolog
activ
highli
oxygen
coumarin
gallic
acidderiv
flavonoid
phenol
hydroxycinnam
acidderiv
kayser
kolodziej
kolodziej
coll
et
al
recent
sulfooxi
sulfooxi
identifi
pelargonium
sidoid
first
time
hauer
et
al
significantli
hauer
et
al
characteris
two
novel
compound
sulfooxi
sulfooxi
fig
novel
compound
screen
pharmacolog
activ
may
repres
individu
activ
constitu
far
remain
elus
interest
note
repertoir
health
condit
pelargonium
sidoid
use
expand
beyond
origin
tradit
use
gastrointestin
disord
includ
respiratori
tract
infect
acut
bronchiti
asthma
sinus
tonsilllopharyng
accordingli
experiment
clinic
research
focus
treatment
respiratori
tract
infect
line
develop
phytopharmaceut
ep
umckaloabo
regard
wide
array
pharmacolog
studi
involv
vitro
tabl
vivo
tabl
randomis
doubleblind
placebocontrol
clinic
trial
tabl
conduct
concomitantli
divers
rang
test
system
use
evalu
pharmacolog
properti
pelargonium
sidoid
approach
characteris
differ
level
complex
includ
antimicrobi
microdilut
assay
antiadhes
assay
use
cell
penicillingentamicinprotect
assay
neuraminidas
inhibit
assay
fibroblastviru
protect
assay
revers
transcriptionpolymeras
chain
reaction
rtpcr
assay
help
deciph
pharmacolog
efficaci
well
possibl
mode
action
involv
heal
process
pelargonium
sidoid
extract
test
exhibit
good
activ
number
virus
includ
influenza
virus
coxsacki
viru
human
coronaviru
respiratori
syncyti
viru
rsv
parainfluenza
viru
herp
simplex
virus
tabl
howev
ep
phytopharmaceut
poor
activ
ic
mgml
highli
pathogen
avian
influenza
viru
micha
et
al
notabl
ep
extract
high
vitro
activ
ic
mgml
theisen
muller
ic
mgml
micha
et
al
attest
use
respiratori
health
condit
author
note
ep
extract
activ
envelop
virus
compar
nonenvelop
virus
adenoviru
adenoviru
human
rhinoviru
interestingli
antivir
bioactiv
ec
isol
phenol
constitu
increas
order
complex
chemic
chain
structur
follow
epigallocatechin
mgml
mgml
gallocatechin
mgml
gallocatechin
mgml
fraction
mgml
theisen
muller
studi
report
poor
direct
virucid
activ
ep
mgml
instead
author
discov
extract
phenol
constitu
impart
antivir
activ
interf
viru
bind
host
cell
receptor
inhibit
neuraminidas
enzym
furthermor
control
viral
infect
may
occur
product
interferon
ifn
host
cell
suggest
therapi
pelargonium
sidoid
may
stimul
innat
immun
system
kolodziej
base
current
state
research
use
vitro
model
clear
mode
action
pelargonium
sidoid
antivir
activ
may
involv
sever
mechan
mode
action
antivir
constitu
pelargonium
sidoid
also
explain
use
vivo
model
exampl
theisen
muller
show
ep
increas
surviv
virusinfect
mice
explain
underli
mechan
involv
tabl
studi
incorpor
molecular
approach
may
help
understand
mechan
action
antivir
activ
constitu
tradit
medicin
extract
pelargonium
sidoid
use
treat
bacterialrel
condit
diarrhoea
dysenteri
tuberculosi
hutch
et
al
south
africa
mani
plant
speci
use
allevi
symptom
tuberculosi
caus
mycobacterium
tuberculosi
fifth
largest
caus
mortal
countri
mcgaw
et
al
pelargonium
sidoid
plant
extract
test
mycobacterium
speci
well
sever
gramposit
bacillu
subtili
enterococcu
faecali
staphylococcu
aureu
streptococcu
pyogen
gramneg
escherichia
coli
proteu
mirabili
helicobact
pylori
bacteria
notabl
ep
moder
vitro
activ
multiresist
staphylococcu
aureu
minimum
inhibitori
concentr
mic
mgml
bacteri
strain
resist
common
antibiot
ciprofloxacin
erythromycin
studi
provid
signific
find
highlight
import
pelargonium
sidoid
potenti
altern
antibacteri
remedi
time
resist
antibiot
fast
becom
medic
challeng
howev
need
paradigm
shift
toward
experiment
provid
biolog
insight
molecular
mechan
involv
observ
vitro
activ
pelargonium
sidoid
butanol
extract
higher
activ
mic
mgml
compar
isol
chemic
entiti
umckalin
mic
mgml
mycobacterium
smegmati
possibl
due
synergist
effect
mativandlela
et
al
efficaci
natur
product
may
due
two
constitu
act
synergist
wherebi
respect
bioactiv
often
diminish
disappear
upon
separ
individu
chemic
entiti
li
vedera
synerg
bioactiv
compound
phytopharmaceut
normal
claim
account
therapeut
effect
wagner
ulrichmerzenich
particular
polyphenol
compound
plant
extract
known
increas
pharmacokinet
rate
antiinfect
constitu
phytopharmaceut
therebi
enhanc
bioavail
wagner
addit
natur
product
also
work
synergist
antibiot
therebi
improv
overal
pharmacokinet
properti
resist
bacteri
strain
schmidt
et
al
howev
moder
mic
suggest
pelargonium
sidoid
constitu
direct
effect
bacteria
thu
studi
attempt
elucid
mode
action
activ
constitu
beil
kilian
conrad
et
al
work
helicobact
pylori
streptococcu
pyogen
demonstr
ep
prevent
bacteria
adher
gastric
agscel
membran
cell
respect
studi
show
possibl
mode
action
bioactiv
constitu
modul
hostbacteria
interact
phagocytosi
prevent
bacteri
attach
substrat
gastric
human
epitheli
cell
therebi
render
pathogen
ineffect
bioactiv
constitu
pelargonium
sidoid
shown
specif
target
adhes
factor
bacteria
rather
epitheli
cell
membran
conrad
frank
immunomodulatori
activ
pelargonium
sidoid
relat
phytopharmaceut
medicin
may
also
account
observ
moder
bioactiv
bacteria
associ
respiratori
diseas
activ
host
cell
macrophag
machineri
kayser
et
al
demonstr
murin
macrophag
infect
leishmania
parasit
induc
product
reactiv
nitrogen
intermediari
inorgan
nitric
oxid
known
antimicrobi
effector
molecul
studi
show
gallic
acid
highli
oxygen
coumarin
umckalin
potent
noinduc
et
al
prove
activ
macrophag
obtain
wt
mice
key
compon
antimicrobi
immun
respons
listeria
monocytogen
product
compar
control
mm
infect
cell
treat
ep
significantli
increas
releas
dosedepend
respons
mgml
mm
mgml
mm
model
infect
macrophag
higher
noinduc
effect
compar
noninfect
macrophag
indic
nonspecif
immun
respons
trigger
diseas
attack
kayser
et
al
et
al
leishmania
majorinfect
macrophagelik
raw
cell
expos
ep
mark
upregul
induc
nitric
oxid
synthas
ino
gene
express
evalu
revers
transcriptionpolymeras
chain
reaction
rtpcr
trun
et
al
diseas
cell
molecular
express
ino
activ
macrophag
stimul
product
high
level
antimicrobi
effector
molecul
nathan
hibb
particular
gallic
acid
one
constitu
ep
kayser
et
al
shown
induc
prolong
ino
mrna
express
leishmaniainfect
cell
addit
releas
tumour
necrosi
factor
interferon
ifn
provid
evid
cytokineinduc
macrophag
activ
play
crucial
role
immun
defenc
mechan
infect
cell
reiner
locksley
experiment
data
shown
tnfinduc
potenti
pelargonium
sidoid
strongli
associ
phenol
constitu
kolodziej
kiderlen
methanol
extract
pelargonium
sidoid
mgml
exhibit
neglig
tnfinduc
potenti
uml
compar
moder
activ
ethyl
acet
uml
nbutanol
uml
fraction
kayser
et
al
significantli
gallic
acid
mgml
led
high
dosedepend
increas
tnfinduc
potenc
uml
infect
cell
radtk
et
al
also
demonstr
concomit
mrna
gene
express
infect
cell
hand
gallic
acid
shown
increas
level
leishmaniainfect
cell
coupl
upregul
mrna
transcript
radtk
et
al
kolodziej
et
al
notabl
umckalin
signatur
chemic
entiti
pelargonium
sidoid
exhibit
poor
cytokin
gene
express
profil
tabl
present
summari
pharmacolog
evalu
use
vivo
anim
model
despit
import
anim
model
evalu
pharmacolog
efficaci
studi
utilis
system
pelargonium
sidoid
andor
relat
formul
good
research
practic
plantderiv
medicin
dictat
vitro
test
back
vivo
ultim
clinic
studi
houghton
et
al
studi
pelargonium
sidoid
adopt
approach
avoid
pitfal
associ
extrapol
vitro
test
result
claim
vivo
activ
efficaci
co
et
al
argu
anim
model
indispens
valid
vitro
activ
take
account
pharmacokinet
metabol
toxicolog
phenomena
base
approach
yu
et
al
tian
et
al
li
et
al
use
vitro
vivo
antivir
model
therebi
obtain
comprehens
pharmacolog
data
includ
efficaci
toxicolog
sever
chines
herbal
medicin
recent
theisen
muller
confirm
vitro
antivir
activ
ep
use
vivo
anim
model
system
therefor
vitro
vivo
model
consid
futur
pelargonium
sidoid
antiinfect
research
addit
research
also
focu
develop
better
vivo
model
system
elucid
actual
mechan
involv
therapeut
process
pelargonium
sidoid
far
remain
unclear
phytopharmaceut
ep
undergon
numer
clinic
evalu
randomis
doubleblind
placebocontrol
trial
incident
clinic
evalu
respiratoryrel
condit
name
acut
bronchiti
acut
rhinosinus
common
cold
chronic
obstruct
pulmonari
diseas
asthma
tabl
clinic
trial
conduct
ep
includ
patient
age
report
result
suggest
pelargonium
sidoid
herbal
medicin
may
effect
treatment
respiratori
infect
caus
bacteria
virus
among
common
respiratori
tract
infect
clinic
studi
evalu
phytopharmaceut
acut
bronchiti
placebocontrol
studi
acut
bronchiti
characteris
acut
inflamm
respiratori
tract
caus
viral
infect
case
matthi
heger
howev
clinic
studi
done
determin
efficaci
treatment
common
respiratori
diseas
despit
limit
benefit
antibiot
therapi
acut
bronchiti
prescrib
case
matthi
heger
background
appropri
treatment
option
requir
prevent
overus
andor
abus
antibiot
regard
phytopharmaceut
pelargonium
sidoidesbas
product
may
provid
altern
therapeut
option
treatment
respiratori
tract
infect
relat
ailment
paramount
import
medicin
plant
phytopharmaceut
safe
caus
undesir
side
effect
patient
howev
despit
long
histori
use
tradit
medicin
dearth
scientif
inform
pertain
safeti
evalu
pelargonium
sidoid
pelargonium
sidoid
extract
ep
caus
obviou
toxic
effect
mice
signific
differ
bodi
weight
bodi
temperatur
well
organ
weight
lung
liver
spleen
kidney
treatment
control
group
theisen
muller
base
clinic
data
toler
treatment
ep
shown
good
adult
children
tabl
nevertheless
commonli
report
advers
event
includ
gastrointestin
complaint
diarrhoea
matthi
et
al
matthi
et
al
matthi
et
al
haidvogl
heger
matthi
heger
bachert
et
al
kamin
et
al
kamin
et
al
nervou
system
complaint
matthi
et
al
respiratori
mediastin
ailment
matthi
et
al
ear
labyrinth
complaint
matthi
et
al
exanthema
haidvogl
heger
tracheiti
epistaxi
lizogub
et
al
allerg
skin
reaction
bachert
et
al
recent
clinic
studi
teschk
et
al
conclud
pelargonium
sidoid
reveal
evid
hepatotox
howev
even
though
advers
event
clinic
studi
report
nonseri
rigor
studi
still
requir
ascertain
safeti
pelargonium
sidoid
relat
formul
addit
toxicolog
studi
involv
toxic
mutagen
test
need
done
evalu
safeti
plant
although
benefit
medicin
plant
wide
acknowledg
need
safeti
evalu
remain
critic
distinguish
toxic
effect
pharmacolog
efficaci
plant
extract
base
numer
studi
report
current
review
compel
experiment
clinic
evid
suggest
pelargonium
sidoid
may
efficaci
respiratori
tract
infect
may
safe
adult
children
stringent
toxicolog
studi
requir
verschaev
van
staden
comprehens
discuss
variou
method
use
evalu
safeti
medicin
plant
besid
local
use
multipurpos
tradit
remedi
pelargonium
sidoid
evolv
intern
phytopharmaceut
commercialis
pelargonium
sidoid
date
back
earli
plant
introduc
europ
tuberculosi
remedi
charl
henri
steven
reportedli
cure
tradit
healer
lesotho
bladt
wagner
brendler
van
wyk
wynberg
et
al
grow
intern
demand
pelargonium
sidoid
root
extract
led
increas
number
gather
well
volum
harvest
plant
materi
evolut
tradit
medicin
exclus
southern
africa
mainli
south
africa
lesotho
success
phytopharmaceut
umckaloabo
creat
pelargonium
industri
involv
network
harvest
local
buyer
processor
intern
pharmaceut
manufactur
dr
willmar
schwabe
gmbh
co
kg
pharmaceut
karlsruh
germani
pelargonium
trade
evolv
larg
unregul
formalis
industri
past
year
unknown
number
harvest
eastern
cape
south
africa
lesotho
collect
sell
plant
materi
local
intermediari
buyer
newton
et
al
organis
trade
medicin
plant
normal
involv
chain
local
dealer
buy
plant
materi
local
collector
eventu
sell
larger
trade
export
compani
lubb
verpoort
eastern
cape
gowar
enterpris
collect
suppli
pelargonium
sidoid
tuber
root
anoth
intermediari
bzh
import
export
respons
dri
shred
packag
onward
rout
parcev
pharmaceut
export
materi
endproduct
manufactur
germani
lesotho
bophelo
process
respons
collect
process
suppli
tuber
parcev
pharmaceut
process
raw
materi
obtain
develop
economi
involv
medicin
plant
trade
still
predominantli
undertaken
european
countri
endproduct
manufactur
lubb
verpoort
also
appli
pelargonium
sidoid
commerci
success
umckaloabo
provid
good
exampl
achiev
welldirect
research
develop
initi
astut
market
gerick
harvest
mainli
reli
wild
collect
pelargonium
sidoid
livelihood
due
limit
altern
econom
opportun
commun
amidst
overal
commerci
success
pelargonium
trade
question
ask
possibl
vulner
harvest
lack
bargain
power
aris
monopolist
market
chain
larg
trade
compani
signific
control
price
system
due
central
role
medicin
plant
trade
coupl
larg
scale
purchas
ownership
critic
infrastructur
perform
sever
function
includ
qualiti
control
lubb
verpoort
howev
despit
challeng
relat
benefici
equiti
medicin
resourc
lesson
aris
pelargonium
sidoid
case
studi
clearli
invalu
futur
natur
product
research
develop
programm
develop
countri
increas
number
medicin
plant
supplier
china
india
mexico
malaysia
export
process
product
endproduct
manufactur
western
countri
lubb
verpoort
pelargonium
industri
may
evolv
tandem
grow
trend
medicin
plant
trade
increas
commerci
demand
pelargonium
sidoid
intern
market
led
localis
uncontrol
indiscrimin
sometim
illeg
harvest
wild
plant
lewu
et
al
lewu
et
al
wynberg
et
al
escal
demand
caus
irrepar
reduct
wild
popul
coll
et
al
may
result
biodivers
threat
pelargonium
sidoid
howev
conserv
statu
pelargonium
sidoid
recent
revis
declin
red
data
list
south
african
plant
least
concern
red
data
list
south
african
plant
lesotho
conserv
statu
pelargonium
sidoid
evalu
addit
plant
list
either
intern
iucn
red
list
threaten
speci
convent
intern
trade
endang
speci
cite
databas
newton
et
al
conspicu
lack
comprehens
data
annual
harvest
trade
volum
pelargonium
sidoid
vari
estim
deriv
data
collect
interview
report
literatur
estim
annual
harvest
fresh
materi
rang
newton
et
al
van
niekerk
wynberg
despit
lack
accur
data
tight
conserv
regul
formul
curb
uncontrol
harvest
south
africa
newton
et
al
notwithstand
occasion
financi
return
obtain
local
commun
overexploit
resourc
may
affect
avail
futur
eastern
cape
plant
slow
regener
rate
significantli
lower
initi
harvest
second
year
lewu
et
al
meet
everexpand
demand
intern
trade
raw
materi
pelargonium
sidoid
may
cultiv
larg
scale
current
plant
cultiv
small
neglig
scale
coll
et
al
also
limit
use
seed
propag
due
low
viabil
coupl
low
germin
lewu
et
al
altern
biotechnolog
tool
plant
tissu
cultur
fig
may
play
critic
role
provis
genet
uniform
clone
pelargonium
industri
moyo
et
al
recent
moyo
et
al
moyo
et
al
press
report
micropropag
acclimatis
procedur
capac
produc
million
uniform
pelargonium
sidoid
clone
throughout
year
long
histori
commerci
product
highvalu
phytochem
use
tissu
cultur
system
canter
et
al
howev
major
challeng
cultiv
medicin
plant
percept
plant
produc
similar
qualiti
bioactiv
compound
wild
plant
white
et
al
moyo
et
al
show
greenhous
produc
plant
similar
bioactiv
compound
wild
plant
term
umckalin
phenol
compound
respect
addit
extract
greenhous
wild
plant
exhibit
compar
antimicrobi
antioxid
properti
moyo
et
al
long
term
product
umckaloabo
may
base
plant
materi
produc
consist
cultiv
practic
cultiv
materi
produc
control
environment
condit
prefer
phytopharmaceut
industri
minimis
qualit
quantit
variat
composit
natur
product
lubb
verpoort
addit
qualiti
phytopharmaceut
improv
use
genet
uniform
clone
elimin
problem
associ
product
adulter
schmidt
et
al
hand
futur
pharmaceut
product
umckaloabo
may
also
eventu
depend
applic
bioreactor
technolog
synthesi
pelargonium
sidoid
bioactiv
compound
coll
et
al
demonstr
abil
transgen
pelargonium
sidoid
hairi
root
cultur
transform
use
agrobacterium
rhizogen
produc
desir
bioactiv
pharmaceut
compound
author
conclud
system
immens
potenti
conserv
strategi
medicin
import
plant
howev
possibl
phytotherapeut
produc
use
biotechnolog
may
readili
accept
consum
natur
medicin
notwithstand
concern
may
inevit
biotechnolog
play
key
role
product
plantderiv
pharmaceut
compound
futur
hairi
root
cultur
transform
use
agrobacterium
rhizogen
often
sustain
stabl
high
product
plant
growth
regulatorfre
medium
canter
et
al
thu
use
biotechnolog
approach
allow
eas
standardis
chemic
constitu
phytopharmaceut
therebi
guarante
consist
qualiti
endproduct
overal
help
avert
current
plant
biodivers
conserv
dilemma
aris
overharvest
practic
wild
popul
despit
emerg
recent
time
highthroughput
screen
synthet
chemic
librari
altern
technolog
pharmaceut
industri
natur
product
remain
vital
compon
drug
discoveri
particular
medicin
plant
offer
sever
advantag
potenti
sourc
novel
chemic
entiti
phytopharmaceut
pharmacolog
activ
demonstr
variou
vitro
vivo
clinic
studi
indic
pelargonium
sidoid
possess
moder
direct
antiinfect
properti
highli
notabl
immunomodulatori
activ
addit
pelargonium
sidoid
root
extract
effect
well
toler
treatment
respiratoryrel
infect
base
experiment
clinic
pharmacolog
evid
transform
pelargonium
sidoid
tradit
medicin
success
phytopharmaceut
provid
compel
argument
continu
explor
medicin
plant
indigen
medic
system
next
gener
phytopharmaceut
even
though
signific
mileston
achiev
pelargonium
sidoid
pharmacolog
research
studi
still
need
fulli
elucid
mechan
action
biolog
principl
underli
therapeut
capac
notabl
bulk
pharmacolog
research
pelargonium
sidoid
skew
toward
respiratori
tract
infect
expens
ailment
plant
use
tradit
african
medicin
clinic
research
also
focu
respiratori
tract
infect
besid
acut
bronchiti
far
attract
attent
furthermor
lack
conclus
data
toxicolog
properti
pelargonium
sidoid
despit
use
tradit
medicin
long
time
stringent
evalu
toxicolog
properti
pelargonium
sidoid
paramount
import
given
extens
use
medicin
formul
long
term
success
commercialis
southern
african
medicin
plant
must
view
much
wider
holist
context
includ
conservationfriendli
practic
sustain
suppli
raw
materi
context
susten
pelargonium
sidoid
phytopharmaceut
industri
requir
innov
approach
utilis
biotechnolog
tool
plant
tissu
cultur
bioreactor
product
genet
uniform
clone
therapeut
secondari
metabolit
respect
